Enhancing poxvirus oncolytic effects through increased spread and immune evasion

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2071-2075

  Kirn, David H ^a   Wang, Yaohe ^b   Liang, Wenchung ^c   Contag, Christopher H ^c   Thorne, Stephen H ^d,e  

^a Jennerex Biotherapeutics   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; METASTASIS; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; VACCINIA; VIRUS INFECTION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LIPID BILAYERS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 42049121876     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6515     Document Type: Article

References (19)

1. Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005;32:537-48.
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
3. Thorne SH, Hwang T-H, O'Gorman BE, et al. Rational strain selection and engineering creates a broad spectrum systemically effective oncolytic poxvirus JX-963. J Clin Invest 2007;117:3350-8.
4. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14:361-70.
5. Buller RM, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev 1991;55:80-122.
6. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002;83:2615-31.
7. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-54.
8. Ichihashi Y. Extracellular enveloped vaccinia virus escapes neutralization. Virology 1996;217:478-85.
9. Mathew EC, Sanderson CM, Hollinshead R, Smith GL. A mutational analysis of the vaccinia virus B5R protein. J Gen Virol 2001;82:1199-213.
10. McIntosh AA, Smith GL. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol 1996;70:272-81.
11. Parkinson JE, Sanderson CM, Smith GL. The vaccinia virus A38L gene product is a 33-kDa integral membrane glycoprotein. Virology 1995;214:177-88.
12. Law M, Hollinshead R, Smith GL. Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol 2002;83:209-22.
13. Carter GC, Rodger G, Murphy BJ, et al. Vaccinia virus cores are transported on microtubules. J Gen Virol 2003;84:2443-58.
14. Blasco R, Sisler JR, Moss B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 1993;67:3319-25.
15. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006;311:1780-4.
16. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000;7:66-73.
17. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004;22:313-20.
18. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004;325:425-31.
19. Putz MM, Midgley CM, Law M, Smith GL. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 2006;12:1310-5.